18+ · Research Use Only · Not for Human Consumption
Semaglutide · Phase 3 · Completed
SELECT
In SELECT, a phase 3 trial of semaglutide in patients 45 years or older with preexisting cardiovascular disease and BMI of 27 or greater, no history of diabetes (n=17,604), the primary endpoint, death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke, occurred in 6.5% on semaglutide against 8.0% on placebo, a hazard ratio of 0.80 (95% CI 0.72 to 0.90) (Lincoff AM et al. N Engl J Med 2023 (SELECT)).
Primara Labs sells some of the compounds covered here. Every figure on this page links to its source and the date it was checked.
Results
The primary endpoint, death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke, occurred in 6.5% on semaglutide against 8.0% on placebo, a hazard ratio of 0.80 (95% CI 0.72 to 0.90).
Side effects reported
In SELECT, discontinuation because of adverse events was 16.6% on semaglutide 2.4 mg, against 8.2% on placebo.
| Event | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Discontinuation for adverse events | 16.6% | 8.2% |
Design
Trial design and sources
- Compound
- Semaglutide
- Phase
- 3
- Population
- Patients 45 years or older with preexisting cardiovascular disease and BMI of 27 or greater, no history of diabetes
- Participants randomised
- 17,604
- Duration
- Not published
- Primary endpoint
- Composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke (time to first event)
- Estimand
- Not stated in the source read
- Read out
- 11 November 2023
Event-driven cardiovascular outcomes trial; mean follow-up 39.8 months. The abstract states no body-weight figure.
Questions
SELECT, answered
What did SELECT find?
In SELECT, a phase 3 trial of semaglutide in patients 45 years or older with preexisting cardiovascular disease and BMI of 27 or greater, no history of diabetes (n=17,604), the primary endpoint, death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke, occurred in 6.5% on semaglutide against 8.0% on placebo, a hazard ratio of 0.80 (95% CI 0.72 to 0.90) (Lincoff AM et al. N Engl J Med 2023 (SELECT)).
What side effects were reported in SELECT?
In SELECT, discontinuation because of adverse events was 16.6% on semaglutide 2.4 mg, against 8.2% on placebo.
Related